Plain-English translation of NCT07459660 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a one-year study testing how well and safely ML007C-MA works for people with Alzheimer's disease who are experiencing hallucinations and delusions—seeing or hearing things that aren't there, or believing things that aren't true. You would be taking this medication to see if it helps reduce these symptoms and if it's safe to use long-term. This study only includes people who have already completed an earlier trial of the same medication.
Hallucinations and delusions can be very distressing for people with Alzheimer's disease and their families. Researchers want to understand whether this medication can safely help these symptoms over a longer period of time, beyond what was learned in earlier studies.
You likely qualify if…
You likely don't qualify if…
You would take the medication by mouth over 52 weeks (one year), with the dose adjusted based on how you're doing and how you tolerate the treatment. You'll have regular visits with the study team to check on your safety and how well the medication is working. Your care partner will help track your symptoms and medication use between visits, and the study team will monitor you closely for any side effects or health concerns.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
United States